OnKure Therapeutics (OKUR) Income from Continuing Operations (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Income from Continuing Operations came in at 15760000.0 in Q1 2026, up 8.05% YoY from 14585658.75 in Q1 2025, and down 10.45% on a QoQ basis from 14269000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Income from Continuing Operations data on file, last reported at 15760000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 8.05% year-over-year to 15760000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63408000.0 (down 0.9% YoY) and the FY2025 annual result came in at 63521000.0, up 56.27% from the prior year.
- Income from Continuing Operations slipped to 15760000.0 in Q1 2026, from 14269000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 21216000.0 in Q4 2023 to a low of 40060000.0 in Q3 2023.
- A 5-year average of 16158588.24 and a median of 15194000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 244.67% — and 2024, when it plunged 189.11%.
- Tracing OKUR's Income from Continuing Operations over 5 years: stood at 14665000.0 in 2022, then jumped by 244.67% to 21216000.0 in 2023, then sank by 189.11% to 18905000.0 in 2024, then grew by 24.52% to 14269000.0 in 2025, then fell by 10.45% to 15760000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 15760000.0 (Q1 2026), 14269000.0 (Q4 2025), and 16206000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | -16.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.74 Mn |
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -14.27 Mn |
| Sep 30, 2025 | -16.21 Mn |
| Jun 30, 2025 | -17.17 Mn |
| Mar 31, 2025 | -17.14 Mn |
| Dec 31, 2024 | -18.91 Mn |
| Sep 30, 2024 | -11.60 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Dec 31, 2023 | 21.22 Mn |
| Sep 30, 2023 | -40.06 Mn |
| Jun 30, 2023 | -35.04 Mn |
| Mar 31, 2023 | -28.00 Mn |
| Dec 31, 2022 | -14.67 Mn |
| Sep 30, 2022 | -14.57 Mn |
| Jun 30, 2022 | -14.05 Mn |
| Mar 31, 2022 | -13.39 Mn |
| Dec 31, 2021 | -24.15 Mn |
| Sep 30, 2021 | -21.62 Mn |